GrayMatters Health Ltd. (GMH)

www.graymatters-health.com

High-Tech Company

TECH VERTICALS

Computer Vision, Digital Health, Healthcare IT, Healthtech, MedTech, Mental Health, PTSD, Telehealth

General Data

Sector	Digital Health
Company Stage:	R&D
Established	2018
Number of Employees	28
Reg. Number:	abCDe

DESCRIPTION

GMH is actively marketing Prism for PTSD, an FDA-cleared device being used today to treat patients with PTSD in a growing list of psychiatry clinics across the US. An expert team in the US is leading commercial growth, market access, medical strategy and training programs.
GMH is the first company to develop a PTSD treatment based on a proprietary amygdala-based digital biomarker.  While medical biomarkers measure tissue to assess disease, the EFP (EEG-fMRI-Pattern) biomarker measures brain activity associated with mental health disorders.
This is the world’s first biomarker that harnesses advanced statistical models to register fMRI amygdala data to readily accessible EEG. This innovation brings the power of evidence-based, precision neurofeedback to any psychiatry clinic treating PTSD patients.

TECHNOLOGY

Prism uses an EEG cap that is paired with interactive audiovisuals to train patients in how to lower the biomarker associated with PTSD, thus regaining control over their brain’s emotional regulation system. By learning how to get agitated avatars to sit down in a virtual office, people with PTSD can regain control over their emotions and lower biomarkers associated with the condition.

Products and Phases

Product	Phase
Prism for PTSD	FDA Approved
Prism for PTSD, uses the amygdala-based biomarker because research has shown that PTSD is associated with hyperactivity of the amygdala, the center of our fight-flight response. Prism for PTSD gathers years of neuroscience research and places it into the hands of mental healthcare providers. Combining an innovative software with an affordable FDA-approved EEG headset for neurofeedback makes it is easy to integrate Prism into any clinic caring for PTSD patients. Designed for rapid deployment, the team is trained in the morning and patients can be treated the same afternoon.

	TARGET MARKETS
	Physicians.

	BUSINESS MODEL
	B2B

CONTACT INFO

Expand / Collapse All

Main Address: Haifa, Israel

Address	82 HaAtsma'ut Rd.
City	Haifa
Country	Israel
Zip	3303403

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Oded Kraft	CEO & President & Co-Founder	Medingo (Head of Products & Business Development)
Dr. Aron Tendler	Chief Medical Officer	Brainsway (Chief Medical Officer)
Prof. Talma Hendler	Chief Medical Scientist & Innovator
Mr. Kirk Thelander	CCO
Mr. Shai Attia	VP, R&D & Co-Founder	Medic Vision (R&D Manager)
Ms. Pam Schwartz	VP, Marketing
Ms. Adar Shani	VP, Clinical & Regulatory & Quality Affairs	Nuvo Group (VP, Clinical & Regulatory Affairs)
Mr. Rani Cohen	Co-Founder	HyperRoll (CEO)

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Executive Chairman	Co-Founder, GrayMatters Health
abC Defghij	Board Member	CEO & Co-Founder, GrayMatters Health
abC Defghij	Board Member	Former VP, Healthcare, Elron Electronic Industries
abC Defghij	Board Member	Executive Chairman & Founder, NeurOptics

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

First Round

Jan. 11, 2022

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Studio	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	High-Tech Company	abCDe	Led the round
abC Defghij	Private Investor	abCDe

Seed

Mar. 04, 2021

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Technology Transfer Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

May. 01, 2024

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Sep. 07, 2022

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Fund	abCDe

R&D Grant

Jul. 18, 2021

R&D

abCDe

Co-op with McLean Hospital Corp.

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Bi-National Fund	abCDe

R&D Grant

Jun. 01, 2021

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Jun. 01, 2020

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

Last Updated:	abCDe
IVC Number:	abCDe